Nanoform grant global starmap AI license to AstraZeneca
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Investment is additive to KKR’s existing health care growth strategy
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Subscribe To Our Newsletter & Stay Updated